SCHEDULE: Indaptus Insider Boosts Stake, Agrees to Board Vote

Jeffery A. Meckler increased his beneficial ownership in Indaptus Therapeutics to 12.7% and entered into a voting agreement supporting board proposals following a $6.0 million preferred stock sale.

Summary

• Jeffery A. Meckler, a reporting person, now beneficially owns 273,103 shares of Indaptus Therapeutics, Inc. common stock, representing 12.7% of the class.
• This ownership includes 229,929 shares of common stock, 16,688 shares issuable from warrants, and 26,486 shares issuable from options.
• Meckler received an additional 216,617 shares of common stock on December 23, 2025, as an equity settlement payment under a Modification Agreement.
• Indaptus Therapeutics entered into a Securities Purchase Agreement on December 22, 2025, with David E. Lazar for the sale of 300,000 Series AA Convertible Preferred Stock and 700,000 Series AAA Convertible Preferred Stock at $6.00 per share, generating $6.0 million in gross proceeds.
• In connection with this, Meckler signed a Voting Agreement, committing to vote his shares in favor of all board-recommended proposals at a special stockholders' meeting related to the Purchase Agreement.
• The Voting Agreement also includes a one-year standstill provision, restricting Meckler from acquiring more securities, engaging in control-seeking activities, or soliciting proxies.

Sentiment

Score: 7

Explanation: The company successfully secured $6.0 million in capital, which is a positive for its financial stability and operations. The reporting person increased their stake through an equity settlement, but also agreed to significant restrictions on their future influence for a year, which could be seen as a trade-off.

Positives

• Jeffery A. Meckler received an equity settlement payment of 216,617 shares of common stock, increasing his beneficial ownership.
• Indaptus Therapeutics secured $6.0 million in gross proceeds from the sale of preferred stock to David E. Lazar, strengthening its financial position.
• The Voting Agreement ensures shareholder support from a significant holder for board-recommended proposals related to the capital raise.

Negatives

• Jeffery A. Meckler is subject to a one-year standstill agreement, restricting his ability to acquire additional shares, engage in proxy solicitations, or seek to influence company management or policies.
• The voting agreement limits Meckler's independent voting discretion on certain matters related to the Purchase Agreement.

Risks

• The standstill agreement limits Jeffery A. Meckler's ability to increase his stake or independently influence company direction for one year, potentially reducing his flexibility as a significant shareholder.
• The requirement for a special meeting of stockholders to approve aspects of the Purchase Agreement introduces a dependency on shareholder approval for the transaction to proceed as planned.

Future Outlook

The Voting Agreement includes a one-year standstill period from the Proxy Effective Date, during which Jeffery A. Meckler is restricted from certain actions related to acquiring company securities or influencing management. A special meeting of stockholders will be called to secure approvals related to the Purchase Agreement.

Industry Context

This filing indicates a capital infusion for Indaptus Therapeutics, a common occurrence for biotechnology or pharmaceutical companies, especially those in development stages, to fund research, clinical trials, or operational expenses. The involvement of a significant shareholder in a voting agreement and standstill provision is a specific corporate governance arrangement often seen in connection with strategic investments or restructurings.

Corporate Governance

Related Party Transactions

• Jeffery A. Meckler, a reporting person (likely an insider), received an equity settlement payment of 216,617 shares of Common Stock from Indaptus Therapeutics, Inc. in connection with a Modification Agreement.

Stakeholder Impact

• Shareholders: The capital raise could dilute existing shareholders if the preferred stock converts to common stock, but it also strengthens the company's financial position. The voting agreement ensures support for board proposals, potentially reducing uncertainty. The standstill agreement limits a significant shareholder's ability to challenge management.
• Company (Indaptus Therapeutics): Benefits from $6.0 million in gross proceeds, enhancing liquidity and funding capabilities. Secures a voting commitment from a key shareholder.
• Jeffery A. Meckler: Increased beneficial ownership but accepted restrictions on future actions and influence for a year.

Next Steps

• A special meeting of stockholders will be called to secure certain stockholder approvals in connection with the Securities Purchase Agreement.

Key Dates

Keywords

Indaptus Therapeutics, Jeffery A. Meckler, Schedule 13D/A, Beneficial Ownership, Common Stock, Preferred Stock, Capital Raise, Voting Agreement, Standstill Agreement, Equity Settlement, SEC Filing, Corporate Governance